These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 1289663)

  • 1. Introductory remarks: development of chemopreventive agents for prostate cancer.
    Kelloff GJ; Boone CW; Malone WF; Steele VE; Doody LA
    J Cell Biochem Suppl; 1992; 16H():1-8. PubMed ID: 1289663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of chemopreventive agents for bladder cancer.
    Kelloff GJ; Boone CW; Malone WF; Steele VE; Doody LA
    J Cell Biochem Suppl; 1992; 16I():1-12. PubMed ID: 1305671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of chemopreventive agents for lung and upper aerodigestive tract cancers.
    Kelloff GJ; Boone CW; Steele VK; Perloff M; Crowell J; Doody LA
    J Cell Biochem Suppl; 1993; 17F():2-17. PubMed ID: 8412195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.
    Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovich L; Malone WA; Crowell JA; Higley HR; Sigman CC
    Urology; 2001 Apr; 57(4 Suppl 1):46-51. PubMed ID: 11295594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
    Lieberman R
    Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention.
    Fujimoto N; Chang C; Nomura M; Matsumoto T
    Urol Int; 2005; 74(4):289-97. PubMed ID: 15897691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprevention of prostate cancer: current status and future directions.
    Lieberman R
    Cancer Metastasis Rev; 2002; 21(3-4):297-309. PubMed ID: 12549768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target populations and strategies for chemoprevention trials of prostate cancer.
    Bostwick DG
    J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention of prostate cancer.
    Kucuk O
    Cancer Metastasis Rev; 2002; 21(2):111-24. PubMed ID: 12465750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention of prostate cancer: guidelines for possible intervention strategies.
    Crawford ED; Fair WR; Kelloff GJ; Lieber MM; Miller GJ; Scardíno PT; DeAntoni EP
    J Cell Biochem Suppl; 1992; 16H():140-5. PubMed ID: 1337764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
    Parnes HL; House MG; Kagan J; Kausal DJ; Lieberman R
    J Urol; 2004 Feb; 171(2 Pt 2):S68-74; discussion S75. PubMed ID: 14713758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate biomarkers of precancer and their application in chemoprevention.
    Kelloff GJ; Malone WF; Boone CW; Steele VE; Doody LA
    J Cell Biochem Suppl; 1992; 16G():15-21. PubMed ID: 1469895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications.
    Chhabra G; Singh CK; Ndiaye MA; Fedorowicz S; Molot A; Ahmad N
    Cancer Lett; 2018 May; 422():9-18. PubMed ID: 29471004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention for prostatic intraepithelial neoplasia.
    Nelson PS; Gleason TP; Brawer MK
    Eur Urol; 1996; 30(2):269-78. PubMed ID: 8875211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is There a Future for Chemoprevention of Prostate Cancer?
    Bosland MC
    Cancer Prev Res (Phila); 2016 Aug; 9(8):642-7. PubMed ID: 27099271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.